EUVIMEDEUVIMED entdecken
Open Access

Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis

Sangwook Oh iD, Fatemeh Khani-Habibabadi, Kevin C O'Connor iD, Aimee S Payne iD

Science Advances · 2025

DOI: 10.1126/sciadv.adt0795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Sangwook Oh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: B-Lymphocytes, Receptors, Cholinergic, Myasthenia Gravis, Autoantibodies. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In acetylcholine receptor (AChR)–seropositive myasthenia gravis (MG), anti-AChR autoantibodies impair neuromuscular transmission and cause severe muscle weakness. MG therapies broadly suppress immune function, risking infections. We designed a chimeric autoantibody receptor (CAAR) expressing the 210–amino acid extracellular domain of the AChR α subunit (A210) linked to CD137-CD3ζ cytoplasmic domains to direct T cell cytotoxicity against anti-AChRα B cells. A210-CAART incorporating a CD8α transmembrane domain (TMD8α) showed functional but unstable surface expression, partially restored by inhibiting lysosomal degradation. A210-CAART with a CD28 TMD showed sustained surface expression, independent of TMD dimerization motifs. In a mouse xenograft model, A210.TMD8α-CAART demonstrated early control of anti-AChR B cell outgrowth but subsequent rebound and loss of surface CAAR expression, whereas A210.TMD28-CAART induced sustained surface CAAR expression and target cell elimination. This study demonstrates the importance of the CD28 TMD for CAAR stability and in vivo function, laying the groundwork for future development of precision cellular immunotherapy for AChR-MG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-LymphocytesReceptors, CholinergicMyasthenia GravisAutoantibodiesT-LymphocytesLymphocyte DepletionAnimalsMiceHumansFemale

Substanzen

Receptors, CholinergicAutoantibodies

Autor:innen und Institutionen

  • Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
  • Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA.

ORCID-Profile: Sangwook Oh, Kevin C O'Connor, Aimee S Payne

Förderung

  • NIAID NIH HHS

Zitieren

APA

Oh, S., Khani-Habibabadi, F., O'Connor, K. C., & Payne, A. S. (2025). Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis. Science Advances. https://doi.org/10.1126/sciadv.adt0795

Vancouver

Oh S, Khani-Habibabadi F, O'Connor KC, Payne AS. Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis. Science Advances. 2025. doi:10.1126/sciadv.adt0795

BibTeX
@article{Oh2025,
  author = {Oh, Sangwook and Khani-Habibabadi, Fatemeh and O'Connor, Kevin C and Payne, Aimee S},
  title = {Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adt0795}
}
Kostenlos starten →